You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 5, 2024

CLINICAL TRIALS PROFILE FOR ETRAVIRINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Etravirine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00042289 ↗ Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 2003-03-01 The purpose of this study is to evaluate the pharmacokinetics (PKs) of antiretroviral (ARV) and tuberculosis (TB) medications in pregnant women and their infants. (Pharmacokinetics are the various interactions between a drug and the body.) This study will also evaluate the PKs of certain ARVs in postpartum women before and after starting hormonal contraceptives. The PKs of these drugs will be evaluated by measuring the amount of medicine present in blood and/or vaginal secretions.
NCT00042289 ↗ Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy Completed National Institute of Allergy and Infectious Diseases (NIAID) 2003-03-01 The purpose of this study is to evaluate the pharmacokinetics (PKs) of antiretroviral (ARV) and tuberculosis (TB) medications in pregnant women and their infants. (Pharmacokinetics are the various interactions between a drug and the body.) This study will also evaluate the PKs of certain ARVs in postpartum women before and after starting hormonal contraceptives. The PKs of these drugs will be evaluated by measuring the amount of medicine present in blood and/or vaginal secretions.
NCT00128830 ↗ A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study Completed Tibotec Pharmaceuticals, Ireland Phase 2 2005-06-01 The purpose of this study is to evaluate the long-term safety and tolerability of etravirine, administered as part of an individually optimized antiretroviral therapy (ART), in human immunodeficiency virus Type 1 (HIV-1) infected participants.
NCT00460382 ↗ Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses Completed Janssen-Cilag Tibotec Phase 2 2007-05-01 The purpose of this study is to look at the safety and efficacy of a combination of 3 new antiretroviral drugs: darunavir, etravirine and MK-0518 (raltegravir) in patients who have multi-resistant viruses and limited treatment options. An optimized background regimen that may include nucleoside reverse transcriptase inhibitors (NRTIs) and enfuvirtide can be added, if possible, to this combination. Patients will undergo treatment for 48 weeks and virological efficacy will be evaluated at week 24.
NCT00460382 ↗ Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses Completed Merck Sharp & Dohme Corp. Phase 2 2007-05-01 The purpose of this study is to look at the safety and efficacy of a combination of 3 new antiretroviral drugs: darunavir, etravirine and MK-0518 (raltegravir) in patients who have multi-resistant viruses and limited treatment options. An optimized background regimen that may include nucleoside reverse transcriptase inhibitors (NRTIs) and enfuvirtide can be added, if possible, to this combination. Patients will undergo treatment for 48 weeks and virological efficacy will be evaluated at week 24.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Etravirine

Condition Name

Condition Name for Etravirine
Intervention Trials
HIV Infections 16
HIV 8
HIV-1 4
HIV-1 Infection 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Etravirine
Intervention Trials
HIV Infections 31
Acquired Immunodeficiency Syndrome 16
Immunologic Deficiency Syndromes 12
Infections 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Etravirine

Trials by Country

Trials by Country for Etravirine
Location Trials
United States 180
South Africa 20
Canada 17
Brazil 15
United Kingdom 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Etravirine
Location Trials
Texas 15
New York 15
California 13
North Carolina 12
Florida 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Etravirine

Clinical Trial Phase

Clinical Trial Phase for Etravirine
Clinical Trial Phase Trials
Phase 4 9
Phase 3 8
Phase 2 12
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Etravirine
Clinical Trial Phase Trials
Completed 41
Terminated 5
Not yet recruiting 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Etravirine

Sponsor Name

Sponsor Name for Etravirine
Sponsor Trials
ViiV Healthcare 9
GlaxoSmithKline 7
National Institute of Allergy and Infectious Diseases (NIAID) 5
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Etravirine
Sponsor Trials
Industry 56
Other 37
NIH 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.